Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32244252

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2020 Jul 2
First author
Palladini G

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Palladini G
      type
      Author
    2. name
      Kastritis E
      type
      Author
    3. name
      Maurer MS
      type
      Author
    4. name
      Zonder J
      type
      Author
    5. name
      Minnema MC
      type
      Author
    6. name
      Wechalekar AD
      type
      Author
    7. name
      Jaccard A
      type
      Author
    8. name
      Lee HC
      type
      Author
    9. name
      Bumma N
      type
      Author
    10. name
      Kaufman JL
      type
      Author
    11. name
      Medvedova E
      type
      Author
    12. name
      Kovacsovics T
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Palladini G
      type
      Author
    2. name
      Kastritis E
      type
      Author
    3. name
      Maurer MS
      type
      Author
    4. name
      Zonder J
      type
      Author
    5. name
      Minnema MC
      type
      Author
    6. name
      Wechalekar AD
      type
      Author
    7. name
      Jaccard A
      type
      Author
    8. name
      Lee HC
      type
      Author
    9. name
      Bumma N
      type
      Author
    10. name
      Kaufman JL
      type
      Author
    11. name
      Medvedova E
      type
      Author
    12. name
      Kovacsovics T
      type
      Author
    bibliography ids
    1. nci-bib-0ee2a0f377228d112282d5a3
    book metadata
    content sha256
    afca0cbe5f1df660e1ef7981a6b6579df398b0e44fb275f408f1b9e84fbfb409
    document type
    citation
    dois
    1. 10.1182/blood.2019004460
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:32244252
    immutable id
    pubmed:32244252@afca0cbe5f1df660e1ef7981a6b6579df398b0e44fb275f408f1b9e84fbfb409
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    1
    name
    Blood
    nlm unique id
    7603509
    pages
    71-80
    volume
    136
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      32244252
      provenance
      batch id
      40d9eae1f1d369f13109
      provider
      NCBI PubMed ESummary
      record sha256
      0151f9a3912366c6b4df861edac85b7c12741e023028e818a5534a2571de4e20
      response sha256
      03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
      retrieved at
      2026-09-09T23:47:52.637547+00:00
      publication date
      display
      2020 Jul 2
      precision
      day
      year
      2020
      publication types
      1. Clinical Trial, Phase III
      2. Comparative Study
      3. Journal Article
      4. Multicenter Study
      5. Randomized Controlled Trial
      6. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/32244252/
      title
      Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.

      Preserved source evidence · Not medical advice